Supernus Pharmaceuticals ... (SUPN)
NASDAQ: SUPN
· Real-Time Price · USD
49.27
0.05 (0.10%)
At close: Oct 15, 2025, 3:59 PM
49.27
0.00%
After-hours: Oct 15, 2025, 04:10 PM EDT
0.10% (1D)
| Bid | 47.67 |
| Market Cap | 2.76B |
| Revenue (ttm) | 665.13M |
| Net Income (ttm) | 64.5M |
| EPS (ttm) | 1.15 |
| PE Ratio (ttm) | 42.84 |
| Forward PE | 22.61 |
| Analyst | Buy |
| Dividends | n/a |
| Ask | 49.96 |
| Volume | 437,572 |
| Avg. Volume (20D) | 831,534 |
| Open | 49.16 |
| Previous Close | 49.22 |
| Day's Range | 48.81 - 49.67 |
| 52-Week Range | 29.16 - 51.78 |
| Beta | 0.78 |
| Ex-Dividend Date | n/a |
About SUPN
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol SUPN
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for SUPN stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsSupernus Pharmaceuticals Inc. is scheduled to release its earnings on
Nov 3, 2025,
after market closes.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
6 days ago
+3.15%
Supernus Pharmaceuticals shares are trading higher...
Unlock content with
Pro Subscription
2 months ago
+13.08%
Supernus Pharmaceuticals shares are trading higher after the company reported better-than-expected Q2 financial results and raised its FY25 sales guidance. Also, Cantor Fitzgerald raised its price target on the stock from $42 to $46.
2 months ago · seekingalpha.com
Supernus Pharmaceuticals, Inc. (SUPN) Q2 2025 Earnings Call TranscriptSupernus Pharmaceuticals, Inc. (NASDAQ:SUPN ) Q2 2025 Earnings Conference Call August 5, 2025 4:30 PM ET Company Participants Jack A. Khattar - Founder, President, CEO, Secretary & Director Timothy C.